Research Overview

The focus of our research is in two major areas: the treatment of patients with solid tumors -- notably neuroblastoma -- and the study of survivors of childhood cancer. In treating patients with neuroblastoma, our approach has been to intensify therapy using high-dose therapy in tandem with stem cell rescue. We are participants in the NANT (New Agents in Neuroblastoma Therapy) consortium and the COG Phase 1 consortium. 

Our translational work in collaboration with Dr. Rani George and Dr. Kim Stegmaier focuses on identification of new targeted agents for neuroblastoma. We have an active targeted radiotherapy clinical trials program, utilizing MIBG therapy, and clinical trials in immunotherapy for neuroblastoma. In research on medical late effects, we have been studying young adult patients with a history of cancer treatment, hoping to delineate the morbidity of a variety of therapies and to introduce screening and prevention in this group of patients. An early mammography trial after chest irradiation has been completed, showing that women who were treated with chest radiation are at significant risk of breast cancer and that mammography detects early tumors in this cohort. A study of MRI detection is underway. 

We are active participants in the largest childhood cancer survivor cohort study, the Childhood Cancer Survivor Study, involving 24 centers and over 17,000 survivors. We have completed an analysis of breast cancers in that cohort, and we are studying risk factors for secondary sarcomas. 

Research Background

Dr. Lisa Diller is the Chief Medical Officer, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and the Vice Chair, Department of Pediatric Oncology, Dana-Farber Cancer Institute. She is also the Director of the Perini Family Survivors Center and the David B. Perini Jr. Quality of Life Clinic at Dana-Farber. She is a Professor of Pediatrics at Harvard Medical School. Dr. Diller received a bachelor's degree from Harvard University and earned her medical degree from the University of California at San Diego. She was a resident at Boston Children's Hospital and did her subspecialty training at Dana-Farber/Boston Children's, where she has been on the faculty for over 20 years. Dr. Diller's research focuses on the late effects of treatment for childhood cancer and genetic cancer predisposition syndromes in childhood. In addition, she investigates novel treatments for pediatric solid tumors, particularly tumors that occur in infants and toddlers.

 

Education

Medical School

University of California, San Diego School of Medicine
1985 San Diego CA

Internship

Boston Children's Hospital
1986 Boston MA

Residency

Boston Children's Hospital
1988 Boston MA

Fellowship

Pediatric Hematology-Oncology Boston Children's Hospital/Dana-Farber Cancer Institute
1991 Boston MA

Publications

  1. Update on Surveillance Guidelines in Emerging Wilms Tumor Predisposition Syndromes. Clin Cancer Res. 2025 Jan 06; 31(1):18-24. View Abstract
  2. Update on Surveillance for Wilms Tumor and Hepatoblastoma in Beckwith-Wiedemann Syndrome and Other Predisposition Syndromes. Clin Cancer Res. 2024 Dec 02; 30(23):5260-5269. View Abstract
  3. Childhood, adolescent and young adulthood cancer risk in BRCA1 or BRCA2 pathogenic variant carriers. J Natl Cancer Inst. 2024 Nov 25. View Abstract
  4. Neuroblastoma Predisposition and Surveillance-An Update from the 2023 AACR Childhood Cancer Predisposition Workshop. Clin Cancer Res. 2024 Aug 01; 30(15):3137-3143. View Abstract
  5. Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field. Radiother Oncol. 2024 09; 198:110384. View Abstract
  6. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2024 Jun 07; 116(6):885-894. View Abstract
  7. Correction to: Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2024 Apr 12. View Abstract
  8. The Association of Race, Ethnicity, and Insurance Status with the Visual Acuity of Retinoblastoma Survivors in the IRIS® Registry. Ophthalmic Epidemiol. 2024 Apr 05; 1-7. View Abstract
  9. Cancer survivorship programs at the Dana-Farber Cancer Institute. J Cancer Surviv. 2024 02; 18(1):34-41. View Abstract
  10. A nursing perspective on inpatient sleep and circadian disruptions for pediatric stem cell transplant patients. Pediatr Blood Cancer. 2024 Mar; 71(3):e30816. View Abstract
  11. Factors influencing parents' choice of palliative treatment goals for children with relapsed or refractory neuroblastoma: A multi-site longitudinal survey study. Cancer. 2024 04 01; 130(7):1101-1111. View Abstract
  12. Assisted reproductive technology use and outcomes in childhood cancer survivors. Cancer. 2024 01 01; 130(1):128-139. View Abstract
  13. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2023 Aug; 70(8):e30418. View Abstract
  14. Neurocognitive outcomes in adult survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer. 2023 09 15; 129(18):2904-2914. View Abstract
  15. Cumulative burden of late, major surgical intervention in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study (CCSS) cohort. Lancet Oncol. 2023 06; 24(6):691-700. View Abstract
  16. Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 03 10; 41(8):1565-1576. View Abstract
  17. Association of Changes in Cancer Therapy Over 3 Decades With Risk of Subsequent Breast Cancer Among Female Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study (CCSS). JAMA Oncol. 2022 Oct 13. View Abstract
  18. Collaboration to Promote Research and Improve Clinical Care in the Evolving Field of Childhood Cancer Predisposition. Cancer Prev Res (Phila). 2022 10 04; 15(10):645-652. View Abstract
  19. Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1675-1682. View Abstract
  20. Predicting chronic morbidity in childhood cancer survivors. Nat Med. 2022 08; 28(8):1539-1540. View Abstract
  21. Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clin Cancer Res. 2022 06 13; 28(12):2579-2586. View Abstract
  22. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. J Clin Oncol. 2022 09 10; 40(26):3047-3056. View Abstract
  23. Advanced Retinoblastoma Presenting with Cataract in a Child with Limited Access to Primary Care. J Pediatr. 2022 08; 247:171-172. View Abstract
  24. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research. J Natl Cancer Inst. 2022 05 09; 114(5):722-731. View Abstract
  25. Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness. J Natl Cancer Inst. 2022 02 07; 114(2):235-244. View Abstract
  26. Estimated Cost-effectiveness of Genetic Testing in Siblings of Newborns With Cancer Susceptibility Gene Variants. JAMA Netw Open. 2021 10 01; 4(10):e2129742. View Abstract
  27. Socioeconomic disparities in survival after high-risk neuroblastoma treatment with modern therapy. Pediatr Blood Cancer. 2021 10; 68(10):e29127. View Abstract
  28. Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights. Genet Med. 2021 07; 23(7):1366-1371. View Abstract
  29. Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2021 07 10; 39(20):2266-2275. View Abstract
  30. Timely pediatric cancer diagnoses: An unexpected casualty of the COVID-19 surge. Pediatr Blood Cancer. 2020 12; 67(12):e28729. View Abstract
  31. Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2020 11 20; 38(33):3851-3862. View Abstract
  32. Clinical Benefits, Harms, and Cost-Effectiveness of Breast Cancer Screening for Survivors of Childhood Cancer Treated With Chest Radiation : A Comparative Modeling Study. Ann Intern Med. 2020 09 01; 173(5):331-341. View Abstract
  33. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View Abstract
  34. Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Eur J Cancer. 2020 07; 133:4-13. View Abstract
  35. Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. J Pain Symptom Manage. 2020 10; 60(4):782-789. View Abstract
  36. Linking population-based registries to identify familial cancer risk in childhood cancer. Cancer. 2020 07 01; 126(13):3076-3083. View Abstract
  37. Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades. JAMA Oncol. 2020 03 01; 6(3):350-357. View Abstract
  38. Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer. 2020 01 15; 126(2):416-424. View Abstract
  39. Autonomous early detection of eye disease in childhood photographs. Sci Adv. 2019 10; 5(10):eaax6363. View Abstract
  40. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. View Abstract
  41. Solid organ transplantation after treatment for childhood cancer: a retrospective cohort analysis from the Childhood Cancer Survivor Study. Lancet Oncol. 2019 10; 20(10):1420-1431. View Abstract
  42. Late-onset anorectal disease and psychosocial impact in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2019 11 01; 125(21):3873-3881. View Abstract
  43. Promoting Breast Cancer Surveillance: The EMPOWER Study, a Randomized Clinical Trial in the Childhood Cancer Survivor Study. J Clin Oncol. 2019 08 20; 37(24):2131-2140. View Abstract
  44. Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2019 08 20; 37(24):2120-2130. View Abstract
  45. Cancer Treatment-Related Infertility: A Critical Review of the Evidence. JNCI Cancer Spectr. 2019 Mar; 3(1):pkz008. View Abstract
  46. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 07; 66(7):e27736. View Abstract
  47. Risk of solid subsequent malignant neoplasms after childhood Hodgkin lymphoma-Identification of high-risk populations to guide surveillance: A report from the Late Effects Study Group. Cancer. 2019 04 15; 125(8):1373-1383. View Abstract
  48. Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2018 Sep 14; JCO2018784595. View Abstract
  49. Perceptions of future health and cancer risk in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Cancer. 2018 08; 124(16):3436-3444. View Abstract
  50. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer. 2018 08 01; 124(15):3220-3230. View Abstract
  51. Late Infection-Related Mortality in Asplenic Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2018 06 01; 36(16):1571-1578. View Abstract
  52. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. Neuro Oncol. 2018 01 10; 20(1):132-142. View Abstract
  53. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View Abstract
  54. Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clin Cancer Res. 2017 07 01; 23(13):e98-e106. View Abstract
  55. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clin Cancer Res. 2017 Jun 15; 23(12):e62-e67. View Abstract
  56. PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e76-e82. View Abstract
  57. Understanding predictors of continued long-term pediatric cancer care across the region: A report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2017 Oct; 64(10). View Abstract
  58. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1327-1334. View Abstract
  59. Neuroblastoma. Nat Rev Dis Primers. 2016 11 10; 2:16078. View Abstract
  60. Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. Int J Radiat Oncol Biol Phys. 2017 02 01; 97(2):270-277. View Abstract
  61. Transition and transfer of childhood cancer survivors to adult care: A national survey of pediatric oncologists. Pediatr Blood Cancer. 2017 02; 64(2):346-352. View Abstract
  62. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 May 01; 2(5):608-615. View Abstract
  63. Chronic Conditions and Utility-Based Health-Related Quality of Life in Adult Childhood Cancer Survivors. J Natl Cancer Inst. 2016 09; 108(9). View Abstract
  64. Breast Cancer Risk in Childhood Cancer Survivors Without a History of Chest Radiotherapy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2016 Mar 20; 34(9):910-8. View Abstract
  65. Health care utilization, lifestyle, and emotional factors and mammography practices in the Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2015 Nov; 24(11):1699-706. View Abstract
  66. Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2015 Sep 10; 33(26):2893-900. View Abstract
  67. An Increased Risk of Second Malignant Neoplasms After Rhabdomyosarcoma: Population-Based Evidence for a Cancer Predisposition Syndrome? Pediatr Blood Cancer. 2016 Feb; 63(2):196-201. View Abstract
  68. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015 Oct; 64(10):1251-60. View Abstract
  69. Childhood Cancer Survivor Study participants' perceptions and understanding of the Affordable Care Act. J Clin Oncol. 2015 Mar 01; 33(7):764-72. View Abstract
  70. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. View Abstract
  71. Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer. 2015 Jan 15; 121(2):286-93. View Abstract
  72. Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. Cancer. 2014 Aug 15; 120(16):2507-13. View Abstract
  73. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med. 2014 May 20; 160(10):661-71. View Abstract
  74. Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2014 Aug 15; 120(16):2514-21. View Abstract
  75. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014 Jul 20; 32(21):2217-23. View Abstract
  76. Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. J Pediatr Hematol Oncol. 2014 Apr; 36(3):237-40. View Abstract
  77. Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation. Leuk Lymphoma. 2014 Nov; 55(11):2477-83. View Abstract
  78. Synchronous small bowel and atypical primary leiomyosarcoma of inferior vena cava in a patient with RB1 mutation. Abdom Imaging. 2014 Feb; 39(1):33-9. View Abstract
  79. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant. 2014 Apr; 49(4):502-8. View Abstract
  80. Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer. 2014 Apr 01; 120(7):1068-75. View Abstract
  81. Partnership for health-2, a web-based versus print smoking cessation intervention for childhood and young adult cancer survivors: randomized comparative effectiveness study. J Med Internet Res. 2013 Nov 05; 15(11):e218. View Abstract
  82. Pulmonary outcomes in survivors of childhood central nervous system malignancies: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014 Feb; 61(2):319-25. View Abstract
  83. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014 Jan; 61(1):53-67. View Abstract
  84. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013 Sep; 14(10):999-1008. View Abstract
  85. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013 Aug; 14(9):873-81. View Abstract
  86. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. J Clin Oncol. 2013 Jun 20; 31(18):2282-8. View Abstract
  87. A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1. Bone Marrow Transplant. 2013 Jul; 48(7):947-52. View Abstract
  88. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012 Oct; 256(4):573-80. View Abstract
  89. Influence of new late effects on quality of life over time in Hodgkin lymphoma Survivors: a longitudinal survey study. Ann Oncol. 2013 Jan; 24(1):226-30. View Abstract
  90. Pediatric Hodgkin lymphoma: trade-offs between short- and long-term mortality risks. Blood. 2012 Sep 13; 120(11):2195-202. View Abstract
  91. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the childhood cancer survivor study. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):224-30. View Abstract
  92. Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Nov; 59(5):902-7. View Abstract
  93. New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Study. J Clin Oncol. 2012 Jun 20; 30(18_suppl):CRA9513. View Abstract
  94. Secondary gastrointestinal cancer in childhood cancer survivors: a cohort study. Ann Intern Med. 2012 Jun 05; 156(11):757-66, W-260. View Abstract
  95. Summaries for patients. Increased risk for gastrointestinal cancer in childhood cancer survivors. Ann Intern Med. 2012 Jun 05; 156(11):I-36. View Abstract
  96. Childhood Cancer Survivor Study participants' perceptions and knowledge of health insurance coverage: implications for the Affordable Care Act. J Cancer Surviv. 2012 Sep; 6(3):251-9. View Abstract
  97. Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study. Leuk Lymphoma. 2012 Aug; 53(8):1474-80. View Abstract
  98. Tumor histology during induction therapy in patients with high-risk neuroblastoma. Pediatr Blood Cancer. 2012 Sep; 59(3):506-10. View Abstract
  99. How confident are young adult cancer survivors in managing their survivorship care? A report from the LIVESTRONG™ Survivorship Center of Excellence Network. J Cancer Surviv. 2011 Dec; 5(4):371-81. View Abstract
  100. Clinical practice. Adult primary care after childhood acute lymphoblastic leukemia. N Engl J Med. 2011 Oct 13; 365(15):1417-24. View Abstract
  101. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011 Aug 04; 118(5):1413-20. View Abstract
  102. Quantifying alkylating agent exposure: Evaluation of the cyclophosphamide equivalent dose-A report from the Childhood Cancer Survivor Study. J Clin Oncol. 2011 May 20; 29(15_suppl):9547. View Abstract
  103. Disseminating a smoking cessation intervention to childhood and young adult cancer survivors: baseline characteristics and study design of the partnership for health-2 study. BMC Cancer. 2011 May 11; 11:165. View Abstract
  104. Survivors of childhood cancer have increased risk of gastrointestinal complications later in life. Gastroenterology. 2011 May; 140(5):1464-71.e1. View Abstract
  105. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011 Mar 04; 108(5):619-28. View Abstract
  106. The current status of follow-up services for childhood cancer survivors, are we meeting goals and expectations: a report from the Consortium for New England Childhood Cancer Survivors. Pediatr Blood Cancer. 2011 Dec 01; 57(6):1062-6. View Abstract
  107. Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2010 Dec 20; 28(36):5327-47. View Abstract
  108. Breastfeeding in survivors of Hodgkin lymphoma treated with chest radiotherapy. Cancer. 2010 Oct 15; 116(20):4866-71. View Abstract
  109. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38. View Abstract
  110. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2010 Aug 20; 28(24):3808-15. View Abstract
  111. Decision analysis to compare treatment strategies for Stage I/favorable histology Wilms tumor. Pediatr Blood Cancer. 2010 Jul 01; 54(7):879-84. View Abstract
  112. Pharmacotherapy of neuroblastoma. Expert Opin Pharmacother. 2010 Jun; 11(9):1467-78. View Abstract
  113. Inconsistent mammography perceptions and practices among women at risk of breast cancer following a pediatric malignancy: a report from the Childhood Cancer Survivor Study. Cancer Causes Control. 2010 Oct; 21(10):1585-95. View Abstract
  114. A model-based estimate of cumulative excess mortality in survivors of childhood cancer. Ann Intern Med. 2010 Apr 06; 152(7):409-17, W131-8. View Abstract
  115. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010 Apr 06; 152(7):444-55; W144-54. View Abstract
  116. Health status of the oldest adult survivors of cancer during childhood. Cancer. 2010 Jan 15; 116(2):497-505. View Abstract
  117. Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: a mailed survey of pediatric oncologists. J Clin Oncol. 2010 Feb 10; 28(5):878-83. View Abstract
  118. Ovarian tissue autologous transplantation to the upper extremity for girls receiving abdominal/pelvic radiation: 20-year follow-up of reproductive endocrine function. J Pediatr Adolesc Gynecol. 2010 Apr; 23(2):107-10. View Abstract
  119. General internist communication about sexual function with cancer survivors. J Gen Intern Med. 2009 Nov; 24 Suppl 2:S407-11. View Abstract
  120. Suicide ideation in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2010 Feb 01; 28(4):655-61. View Abstract
  121. Caring for cancer survivors: a survey of primary care physicians. Cancer. 2009 Sep 15; 115(18 Suppl):4409-18. View Abstract
  122. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009 Aug 19; 101(16):1131-40. View Abstract
  123. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol. 2009 Aug 20; 27(24):3901-7. View Abstract
  124. Preferences and knowledge gaps among pediatric oncologists regarding the care of childhood cancer survivors: A survey of nearly 1,200 physicians. J Clin Oncol. 2009 May 20; 27(15_suppl):6561. View Abstract
  125. Cancer care and cancer survivorship care in the United States: will we be able to care for these patients in the future? J Oncol Pract. 2009 May; 5(3):119-23. View Abstract
  126. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009 May 10; 27(14):2339-55. View Abstract
  127. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA. 2009 Jan 28; 301(4):404-14. View Abstract
  128. The LIVESTRONG Survivorship Center of Excellence Network. J Cancer Surviv. 2009 Mar; 3(1):4-11. View Abstract
  129. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26. View Abstract
  130. Long-term smoking cessation outcomes among childhood cancer survivors in the Partnership for Health Study. J Clin Oncol. 2009 Jan 01; 27(1):52-60. View Abstract
  131. Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2008 Nov; 51(5):589-92. View Abstract
  132. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008 Oct 16; 455(7215):975-8. View Abstract
  133. New primary sarcomas in survivors of childhood cancer: A detailed analysis of the effects of treatment: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008 May 20; 26(15_suppl):10007. View Abstract
  134. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008 Mar 19; 299(11):1315-9. View Abstract
  135. Treatment of recurrent clear cell sarcoma of the kidney with brain metastasis. Pediatr Blood Cancer. 2008 Feb; 50(2):246-9. View Abstract
  136. Health practice in long-term survivors of Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):468-76. View Abstract
  137. Laparoscopic oophoropexy prior to radiation for pediatric brain tumor and subsequent ovarian function. Hum Reprod. 2008 Jan; 23(1):117-21. View Abstract
  138. Screening adult survivors of childhood cancer with the distress thermometer: a comparison with the SCL-90-R. Psychooncology. 2007 Nov; 16(11):1046-9. View Abstract
  139. The effects of response bias on self-reported quality of life among childhood cancer survivors. Qual Life Res. 2007 Sep; 16(7):1211-20. View Abstract
  140. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One. 2007 Feb 28; 2(2):e255. View Abstract
  141. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2007 Feb 21; 99(4):300-8. View Abstract
  142. Perceptions of breast cancer risk and cancer screening: a qualitative study of young, female Hodgkin's disease survivors. J Cancer Educ. 2007; 22(1):42-6. View Abstract
  143. Transitioning to survivorship: a pilot study. J Pediatr Oncol Nurs. 2006 Nov-Dec; 23(6):335-43. View Abstract
  144. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study. Clin Cancer Res. 2006 Oct 01; 12(19):5693-7. View Abstract
  145. A novel pattern of transaminase elevation associated with autologous transplant for neuroblastoma. Pediatr Transplant. 2006 Sep; 10(6):669-76. View Abstract
  146. Suicidal ideation and attempts in adult survivors of childhood cancer. J Clin Oncol. 2006 Aug 20; 24(24):3852-7. View Abstract
  147. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006 Jun 20; 24(18):2891-6. View Abstract
  148. A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. Ann Oncol. 2005 Dec; 16(12):1949-55. View Abstract
  149. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005 Sep 20; 23(27):6466-73. View Abstract
  150. Perioperative management of a child with severe hypertension from a catecholamine secreting neuroblastoma. Paediatr Anaesth. 2005 Jul; 15(7):606-10. View Abstract
  151. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg. 2005 Jun; 40(6):936-41; discussion 941. View Abstract
  152. Neuropsychological resiliency after treatment for advanced stage neuroblastoma. Bone Marrow Transplant. 2005 Jun; 35(11):1117-22. View Abstract
  153. CT-guided radiofrequency ablation of pediatric Wilms tumor in a solitary kidney. Pediatr Radiol. 2005 Sep; 35(9):923-8. View Abstract
  154. Sarcomas as a subsequent malignancy in survivors of pediatric malignancy:The Childhood Cancer Survivor Study. J Clin Oncol. 2005 Jun; 23(16_suppl):8515. View Abstract
  155. A phase I study of decitabine (DCT) in combination with doxorubicin (DOX) and cyclophosphamide (CTX) in the treatment of relapsed or refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol. 2005 Jun; 23(16_suppl):8530. View Abstract
  156. Second cancers screening in pediatric cancer survivors: A single institution study. J Clin Oncol. 2005 Jun; 23(16_suppl):8538. View Abstract
  157. Sodium reduction for hypertension prevention in overweight adults: further results from the Trials of Hypertension Prevention Phase II. J Hum Hypertens. 2005 Jan; 19(1):33-45. View Abstract
  158. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med. 2004 Oct 19; 141(8):590-7. View Abstract
  159. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004 Aug 01; 22(15):3139-48. View Abstract
  160. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. Journal of Clinical Oncology. 2004; 22(15):3139-3148. View Abstract
  161. Recurrent neuroblastoma: Randomized treatment with topotecan + cyclophosphamide (T+C) vs. topotecan alone(T). A POG/CCG Intergroup Study. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8512. View Abstract
  162. A feasibility study of tamoxifen chemoprevention in Hodgkin's disease (HD) survivors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):8551. View Abstract
  163. Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr. 2004 Apr; 144(4):444-8. View Abstract
  164. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness. Cancer Res. 2004 Feb 01; 64(3):928-33. View Abstract
  165. A feasibility study of tamoxifen chemotherapy prevention in Hodgkin’s disease (HD) survivors. Long-Term Complications of Treatment of Children and Adolescents for Cancer. 2004; (Ontario). View Abstract
  166. Transitioning to survivorship: a pilot study. Long-Term Complications of Treatment of Children and Adolescents for Cancer. 2004; (Ontario). View Abstract
  167. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. J Clin Oncol. 2003 Dec 15; 21(24):4505-9. View Abstract
  168. The TP53, BRCA1 and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin’s disease with second primary neoplasms. Journal of Clinical Oncology. 2003; 21(24):4505-9. View Abstract
  169. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol. 2003 Dec 01; 158(11):1108-13. View Abstract
  170. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003 Dec 01; 21(23):4386-94. View Abstract
  171. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol. 2003 Dec; 25(12):934-40. View Abstract
  172. Utility of routine psychological screening in the childhood cancer survivor clinic. J Clin Oncol. 2003 Mar 01; 21(5):787-92. View Abstract
  173. Utility of routine psychological screening in the childhood cancer survivor clinic. Journal of Clinical Oncology. 2003; 21(5):787-92. View Abstract
  174. Angiogenesis inhibitor TNP-470 during bone marrow transplant and in minimal residual disease. Transplantation in Hematology and Oncology II, Berdel WE, et al, eds. 2003; 283-298. View Abstract
  175. Rapid Sequence Tandem Transplant in Children with High-Risk Neruroblastoma. Transplantation in Hematology and Oncology II, Berdel WE, et al, eds. 2003; 270-279. View Abstract
  176. Satellite DNA hypomethylation in karyotyped Wilms tumors. Cancer Genetics and Cytogenetics. 2003; 141(2):97-105. View Abstract
  177. Primary tumor control in patients with stage 3 and 4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. Journal of Pediatric Hematology/Oncology. 2003; 25(12):934-40. View Abstract
  178. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin disease: report from the Late Effects Study Group (LESG). Journal of Clinical Oncology. 2003; 21(23):4386-94. View Abstract
  179. Successful purging of stem cell products using CD34 selection. Transplantation in Hematology and Oncology II, Berdel WE, et al, eds. 2003; 116-129. View Abstract
  180. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol. 2002 Apr 15; 20(8):2085-91. View Abstract
  181. Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the childhood cancer survivor study. J Clin Oncol. 2002 Mar 15; 20(6):1608-16. View Abstract
  182. MYCN copy number and hyperdiploidy: do they define a favourable prognostic group in neuroblastoma patients between 12 and 24 months of age? A COG study. Advances in Neuroblastoma Research. 2002; (Paris ). View Abstract
  183. Neuropsychological and psychosocial resiliency in children treated for neuroblastoma. Advances in Neuroblastoma Research. 2002; (Paris). View Abstract
  184. Breast cancer screening in women previously treated for Hodgkin’s disease: A prospective cohort study. Journal of Clinical Oncology. 2002; 20(8):2085-2091. View Abstract
  185. Predictors of Smoking Initiation and Cessation Among Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology. 2002; 20(6):1608-1616. View Abstract
  186. Rapid sequence tandem transplant for advanced neuroblastoma: update and patterns of relapse. Advances in Neuroblastoma Research. 2002; (Paris). View Abstract
  187. RB1 genetic testing as a clinical service: a follow-up study. Med Pediatr Oncol. 2001 Oct; 37(4):372-8. View Abstract
  188. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene. 2001 Jul 27; 20(33):4441-9. View Abstract
  189. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res. 2001 Apr; 7(4):1026-32. View Abstract
  190. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer. 2001 Feb 01; 91(3):613-21. View Abstract
  191. Angiogenesis inhibitor TNP-470 during bone marrow transplant: Safety in a preclinical model. Clinical Cancer Research. 2001; 7:1026-32. View Abstract
  192. CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies. Med Pediatr Oncol. 2000 Dec; 35(6):677-82. View Abstract
  193. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):696-700. View Abstract
  194. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol. 2000 Jul; 18(13):2567-75. View Abstract
  195. Characteristics and outcome of children with Beckwith-Wiedemann syndrome and Wilms' tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2000 May; 18(10):2026-31. View Abstract
  196. Measurement of problem-solving deficits in adults with acquired brain damage. J Head Trauma Rehabil. 2000 Feb; 15(1):724-33. View Abstract
  197. ADHD, divorce, and parental disagreement about the diagnosis and treatment. J Dev Behav Pediatr. 2000 Feb; 21(1):53-5. View Abstract
  198. Center surround receptive field structure of cone bipolar cells in primate retina. Vision Res. 2000; 40(14):1801-11. View Abstract
  199. Characteristics and outcome of children with Beckwith-Weidemann syndrome and Wilms tumor: a report from the National Wilms Tumor Study Group. Journal of Clinical Oncology. 2000; 18:2026-31. View Abstract
  200. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. Journal of Clinical Oncology. 2000; 18(13):2567-75. View Abstract
  201. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999 Apr; 17(4):1259. View Abstract
  202. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin’s disease. Journal of Clinical Oncology. 1999; 4:1259-66. View Abstract
  203. Constitutional WT1 mutations in Wilms' tumor patients. J Clin Oncol. 1998 Nov; 16(11):3634-40. View Abstract
  204. Severe ototoxicity following carboplatin-containing conditioning regimen for autologous marrow transplantation for neuroblastoma. Bone Marrow Transplant. 1998 Oct; 22(7):669-74. View Abstract
  205. Childhood cancer predisposition: applications of molecular testing and future implications. J Pediatr. 1998 Mar; 132(3 Pt 1):389-97. View Abstract
  206. Cystic neuroblastoma: emphasis on gene expression, morphology, and pathogenesis. Pediatr Dev Pathol. 1998 Jan-Feb; 1(1):17-28. View Abstract
  207. Constitutional WT1 mutations in Wilms tumor patients. Journal of Clinical Oncology. 1998; 11:3634-40. View Abstract
  208. Cystic neuroblastoma: emphasis on gene expression, morphology, and pathogenesis. Pediatric and Developmental Pathology. 1998; 1:17-28. View Abstract
  209. The case of the missing methylphenidate. Pediatrics. 1997 Oct; 100(4):730-1. View Abstract
  210. Inducing amenorrhea during bone marrow transplantation. A pilot study of leuprolide acetate. J Reprod Med. 1997 Sep; 42(9):537-41. View Abstract
  211. Epidemiology of cancer in childhood.Eds. Nathan DG, Orkin SH. In: Nathan and Oski’s Hematology of Infancy and Childhood. 1997; 1071-91. View Abstract
  212. Use of growth hormone for non-growth hormone deficient children. JAMA. 1996 Dec 18; 276(23):1877-8; author reply 1878. View Abstract
  213. Germline WT1 mutations in Wilms' tumor patients: preliminary results. Med Pediatr Oncol. 1996 Nov; 27(5):404-7. View Abstract
  214. Percutaneous biopsy for prognostic testing of neuroblastoma. Radiology. 1996 Jul; 200(1):213-6. View Abstract
  215. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease. J Infect Dis. 1996 Jan; 173(1):256-8. View Abstract
  216. Pediatric large volume peripheral blood progenitor cell collections from patients under 25 kg: a primer. J Clin Apher. 1996; 11(4):195-203. View Abstract
  217. Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin’s disease. Journal of Infectious Diseases. 1996; 173(1):256-8. View Abstract
  218. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med. 1995 Dec 01; 123(11):828-34. View Abstract
  219. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995 Apr; 95(4):1606-11. View Abstract
  220. A new technique for laparoscopic prophylactic oophoropexy prior to cranial irradiation in children with medulloblastoma. Adolescent and Pediatric Gynecology. 1995; 8:77-81. View Abstract
  221. Preferential amplification of the paternal allele in neuroblastomas with n-myc amplification. In: Advances in Neuroblastoma Research. 1994; 39-43. View Abstract
  222. Overview of Familial Cancers. Genetic Resource. 1994; 8:12-19. View Abstract
  223. Preferential amplification of the paternal allele in neuroblastomas with N-myc amplification. Prog Clin Biol Res. 1994; 385:43-9. View Abstract
  224. Screening children at genetic risk of cancer. Curr Opin Pediatr. 1993 Dec; 5(6):712-5. View Abstract
  225. Prenatal detection of neuroblastoma: a ten-year experience from the Dana-Farber Cancer Institute and Children's Hospital. Pediatrics. 1993 Sep; 92(3):358-64. View Abstract
  226. Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet. 1993 Jun; 4(2):191-4. View Abstract
  227. Cognitive remediation in traumatic brain injury: update and issues. Arch Phys Med Rehabil. 1993 Feb; 74(2):204-13. View Abstract
  228. Stress, appraisal, and coping in mothers of disabled and nondisabled children. J Pediatr Psychol. 1992 Oct; 17(5):587-605. View Abstract
  229. Structure and expression of the Xenopus retinoblastoma gene. Dev Biol. 1992 Sep; 153(1):141-9. View Abstract
  230. Rhabdomyosarcoma and other soft tissue sarcomas of childhood. Curr Opin Oncol. 1992 Aug; 4(4):689-95. View Abstract
  231. Identification of cancer-prone individuals: p53 and family cancer syndromes. J Natl Cancer Inst Monogr. 1992; (12):123-4. View Abstract
  232. Cancer Survivor Initiative Project (National Cancer Institute Contract MAO NCICC)-84332 (PI:Patenaude). Curriculum for health care providers working with young adult survivors. Co-author of medical information summaries section of curriculum. 1992. View Abstract
  233. Neuroblastoma. The Fetus. 1991; 1:1-4. View Abstract
  234. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 1990 Nov; 10(11):5772-81. View Abstract
  235. Parameters of emotional processing in neuropsychiatric disorders: conceptual issues and a battery of tests. J Commun Disord. 1990 Aug-Oct; 23(4-5):247-71. View Abstract
  236. First year after stroke: tracking cognitive and affective deficits. Arch Phys Med Rehabil. 1989 Apr; 70(4):297-302. View Abstract
  237. Unilateral spatial neglect: biases in contralateral search and fine spatial attention. Arch Clin Neuropsychol. 1988; 3(3):213-25. View Abstract
  238. Proper and common nouns: form class judgments in Broca's aphasia. Brain Lang. 1986 May; 28(1):114-25. View Abstract
  239. Psychosocial aspects of living with cancer: a review of the literature. Int J Psychiatry Med. 1981-1982; 11(4):303-29. View Abstract
  240. Assessment and treatment of psychosocial problems of the cancer patient: a case study. Cancer Nurs. 1980 Apr; 3(2):111-9. View Abstract
  241. Male contraception and family planning: a social and historical review. Fertil Steril. 1977 Dec; 28(12):1271-9. View Abstract
  242. Rehabilitation performance and adjustment in stroke patients: a study of social class factors. Genet Psychol Monogr. 1976 May; 93(2):287-352. View Abstract
  243. The effect of hyperbaric oxygen on communication function in adults with aphasia secondary to stroke. J Speech Hear Res. 1972 Mar; 15(1):42-8. View Abstract
  244. The effect of hyperbaric oxygen on the mental and verbal ability of stroke patients. Stroke. 1972 Jan-Feb; 3(1):10-5. View Abstract
  245. Music as a facilitator for visual motor sequencing tasks in children with cerebral palsy. Dev Med Child Neurol. 1971 Jun; 13(3):335-42. View Abstract
  246. Perceptual and intellectual problems in hemiplegia: implications for rehabilitation. Med Clin North Am. 1969 May; 53(3):575-83. View Abstract
  247. The relationship between impersistence, intellectual function and outcome of rehabilitation in patients with left hemiplegia. Neurology. 1968 Sep; 18(9):852-61. View Abstract
  248. The effects of oxygen inhalation on motor impersistence in brain-damaged individuals: a double-blind study. Neurology. 1967 Oct; 17(10):1003-10. View Abstract
  249. Follow-up study of the results of anterior choroidal artery occlusion and subtemporal chemopallidectomy in parkinson's disease: an independent appraisal. J Am Geriatr Soc. 1956 Dec; 4(12):1249-57. View Abstract

Contact Lisa R. Diller

Print Profile